为了提高投资者对抗衰老生物技术的兴趣, 
StimCell Energetics hired Stonegate Capital to boost investor interest in its anti-aging biotech technology.
StimCell Energetics已聘请Stonegate Capital Partners，以提升机构投资者的兴趣，自2026年3月12日起生效，签订为期12个月的协议。 StimCell Energetics has hired Stonegate Capital Partners to boost institutional investor interest, effective March 12, 2026, under a 12-month agreement. 斯通盖特将提供季度研究,投资者关系支持和会议协调以换取25万股普通股,但须经过六个月的保留期及监管合规. Stonegate will provide quarterly research, investor relations support, and meeting coordination in exchange for 250,000 shares of common stock, subject to a six-month hold and regulatory compliance. 生物技术公司的eBalance技术, 以老化,胰岛素抵抗性,高血压,神经病变和功能为目标. The move aims to increase visibility for the biotech firm’s eBalance technology, which targets aging, insulin resistance, high blood pressure, neuropathy, and kidney function. 包含前性陈述,并指出风险. Forward-looking statements are included, with risks noted. 没有进行监管审查. No regulatory review has occurred.
